Drug intelligence / Profile preview

sevelamer carbonate + irbesartan

Development stage: Preclinical
Lead developer: Sanofi
Modality: Small Molecules
Administration: Oral

Overview

This combination consists of sevelamer carbonate, a phosphate binder used to control high blood levels of phosphorus in people with chronic kidney disease who are on dialysis, and irbesartan, an angiotensin II receptor blocker (ARB) used to treat hypertension. Sevelamer carbonate works by binding phosphorus from foods in the digestive tract, preventing its absorption into the bloodstream. Irbesartan works by blocking angiotensin II, a substance that causes blood vessels to tighten, resulting in relaxation of blood vessels and lowering of blood pressure.

Targets

AGTR1 (Angiotensin II Type-1 receptor)

Beyond the preview

Go deeper on sevelamer carbonate + irbesartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sevelamer carbonate + irbesartan.

Explore the full profile